HK1250935A1 - 穩定的包含cd147單克隆抗體的藥物製劑 - Google Patents

穩定的包含cd147單克隆抗體的藥物製劑

Info

Publication number
HK1250935A1
HK1250935A1 HK18110416.5A HK18110416A HK1250935A1 HK 1250935 A1 HK1250935 A1 HK 1250935A1 HK 18110416 A HK18110416 A HK 18110416A HK 1250935 A1 HK1250935 A1 HK 1250935A1
Authority
HK
Hong Kong
Prior art keywords
monoclonal antibody
pharmaceutical preparation
preparation stably
stably
pharmaceutical
Prior art date
Application number
HK18110416.5A
Other languages
English (en)
Inventor
唐浩
馮強
楊天一
陳明曦
Original Assignee
陳小春
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 陳小春 filed Critical 陳小春
Publication of HK1250935A1 publication Critical patent/HK1250935A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK18110416.5A 2016-12-30 2018-08-14 穩定的包含cd147單克隆抗體的藥物製劑 HK1250935A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611271104 2016-12-30

Publications (1)

Publication Number Publication Date
HK1250935A1 true HK1250935A1 (zh) 2019-01-18

Family

ID=62710223

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110416.5A HK1250935A1 (zh) 2016-12-30 2018-08-14 穩定的包含cd147單克隆抗體的藥物製劑

Country Status (5)

Country Link
US (1) US11027016B2 (zh)
EP (1) EP3563869A4 (zh)
CN (1) CN108261544B (zh)
HK (1) HK1250935A1 (zh)
WO (1) WO2018121580A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108261391B (zh) 2016-12-30 2022-03-01 江苏太平洋美诺克生物药业有限公司 稳定的包含cd147单克隆抗体的药物制剂
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
CN113925963B (zh) * 2021-10-15 2023-08-11 江苏太平洋美诺克生物药业股份有限公司 一种稳定的包含抗cd147单克隆抗体的药物制剂
CN114137202B (zh) * 2022-01-12 2023-12-01 杭州隆基生物技术有限公司 单克隆抗体保存液

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
CN1186445C (zh) * 2002-03-15 2005-01-26 陈志南 抗人肝癌单克隆抗体HAb18轻、重链可变区基因及其应用
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
CA2708869C (en) * 2007-12-21 2016-06-28 F. Hoffmann-La Roche Ag Antibody formulation
CN102316898A (zh) * 2008-09-29 2012-01-11 森托科尔奥索生物科技公司 抗cd147抗体、方法和用途
CN101598731B (zh) * 2009-05-07 2013-04-24 陈志南 一种用于肿瘤病理诊断用途的免疫组织化学诊断试剂盒
CN107496917B (zh) * 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
WO2011112566A2 (en) * 2010-03-11 2011-09-15 Abbott Laboratories Basigin binding proteins
JP6054861B2 (ja) * 2010-03-26 2016-12-27 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
CN102961745B (zh) * 2012-09-27 2015-02-18 苏州康聚生物科技有限公司 抗体组合物制剂及其应用
CA2889488A1 (en) * 2012-11-01 2014-05-08 Abbvie Inc. Stable dual variable domain immunoglobulin protein formulations
WO2015160853A2 (en) * 2014-04-16 2015-10-22 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd147
CN104086654B (zh) * 2014-07-04 2016-06-08 中国人民解放军第四军医大学 人源化修饰型抗CD147嵌合抗体HcHAb18及其应用
US9963506B2 (en) * 2015-10-07 2018-05-08 Fourth Military Medical University Human-mouse chimeric anti-CD147 antibody with non-fucosylated glycosylation

Also Published As

Publication number Publication date
WO2018121580A1 (zh) 2018-07-05
EP3563869A4 (en) 2020-08-26
US11027016B2 (en) 2021-06-08
CN108261544B (zh) 2023-05-05
CN108261544A (zh) 2018-07-10
EP3563869A1 (en) 2019-11-06
US20190358324A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
SG11202001368SA (en) Antigen-binding proteins tatrgeting shared antigens
ZA201900353B (en) Anti-pd-l1 antibodies
IL262295A (en) Antibodies against pd-l1
HK1257646A1 (zh) 包含雙特異性抗體建構物之醫藥組合物
IL253909A0 (en) Humanized *anti–muc1 antibodies
HK1250937A1 (zh) 穩定的包含cd147單克隆抗體的藥物製劑
SG10201603721TA (en) Anti-CTLA-4 Antibodies
SG11201706505PA (en) Stable liquid formulation for monoclonal antibodies
IL256097A (en) Antibody epitope
IL264502B1 (en) Anti-cd3 antibody formulations
GB201703063D0 (en) Stabilized antibody protein solutions
EP3567053A4 (en) MONOCLONAL ANTI-CLAUDIN-2 ANTIBODY
HK1250935A1 (zh) 穩定的包含cd147單克隆抗體的藥物製劑
EP3103811A4 (en) Anti-tissue factor monoclonal antibody
HK1255877A1 (zh) 含有抗人tslp受體抗體的藥物組合物
GB201703062D0 (en) Stabilized antibody protein solutions
ZA202004675B (en) Pharmaceutical combinations comprising an anti-ly75 antibody
IL267271A (en) Antibodies against il-5
EP3330376A4 (en) ANTI-EVA 1 PROTEIN ANTIBODY
IL260083A (en) Antibody against myl9
HUE054261T2 (hu) Antitest variánsok
IL272951A (en) antibody variants
EP3362093A4 (en) MONOCLONAL ANTIBODIES NEUTRALIZING HEPARANASE
GB201621907D0 (en) Antibody epitope
GB201511196D0 (en) Monoclonal antibodies